×
About 12,118 results

ALLMedicine™ Neuroblastoma Center

Research & Reviews  4,488 results

Automated Tumor Count for Mitosis-Karyorrhexis Index Determination in Neuroblastoma Usi...
https://doi.org/10.1177/10935266221093597
Pediatric and Developmental Pathology : the Official Jour... Yu G, Yu C et. al.

May 17th, 2022 - Mitosis-karyorrhexis index (MKI) is important for risk stratification workup of neuroblastic tumors. MKI is calculated by estimating the denominator (5000 tumor cells). We hypothesized that whole slide image (WSI) with appropriate digital image an...

Treatment outcomes among high-risk neuroblastoma patients receiving non-immunotherapy r...
https://doi.org/10.1002/pbc.29757
Pediatric Blood & Cancer; Suwannaying K, Monsereenusorn C et. al.

May 14th, 2022 - Neuroblastoma is the most common extracranial malignant solid tumor during childhood. Despite intensified treatment, patients with high-risk neuroblastoma (HR-NBL) still carry a dismal prognosis. The Thai Pediatric Oncology Group (ThaiPOG) propose...

The emerging role of NR2F1-AS1 in the tumorigenesis and progression of human cancer.
https://doi.org/10.1016/j.prp.2022.153938
Pathology, Research and Practice; Luo D, Liu Y et. al.

May 14th, 2022 - Long noncoding RNAs (lncRNAs) are transcripts of more than 200 nucleotides that lack the ability to encode protein. Convincing studies have indicated that lncRNAs can act as oncogenes or tumor suppressors by regulating gene expression. The novel l...

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
https://clinicaltrials.gov/ct2/show/NCT04086485

May 13th, 2022 - Background: Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. While the tr...

Validating Pain Scales in Children and Young Adults
https://clinicaltrials.gov/ct2/show/NCT01639950

May 13th, 2022 - Background: Pain is a common symptom among children with a variety of medical illnesses. Currently, a number of rating scales are used to assess pain interference and pain severity in adults. However, relatively few measures assessing these variab...

see more →

Guidelines  1 results

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696761
British Journal of Cancer; Beiske K, Burchill SA et. al.

Apr 30th, 2009 - Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task...

see more →

Drugs  48 results see all →

Clinicaltrials.gov  157 results

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
https://clinicaltrials.gov/ct2/show/NCT04086485

May 13th, 2022 - Background: Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. While the tr...

Validating Pain Scales in Children and Young Adults
https://clinicaltrials.gov/ct2/show/NCT01639950

May 13th, 2022 - Background: Pain is a common symptom among children with a variety of medical illnesses. Currently, a number of rating scales are used to assess pain interference and pain severity in adults. However, relatively few measures assessing these variab...

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
https://clinicaltrials.gov/ct2/show/NCT03206060

May 13th, 2022 - Background: Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare tumors arising from neural crest tissue that can develop in sympathetic and parasympathetic paraganglia throughout the body. Those arising in the adrenal gland are called PHEOs whi...

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
https://clinicaltrials.gov/ct2/show/NCT05012098

May 13th, 2022 - Background: Olfactory neuroblastoma (ONB, also known as esthesioneuroblastoma), is a rare malignant neoplasm of the nasal cavity. At diagnosis, ONB is often locally advanced. It tends to invade locally and has high rates of regional spread to the ...

Patients Who Receive 131 I-MIBG
https://clinicaltrials.gov/ct2/show/NCT04770831

May 12th, 2022 - This is an observational, single institution study designed to determine the benefit of 131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumo...

see more →

News  150 results

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/fda-accepts-nda-resubmission-for-pedmark-in-prevention-of-platinum-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/nda-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma
https://www.onclive.com/view/activating-the-immune-system-could-be-key-to-treating-pediatric-neuroblastoma

Mar 10th, 2022 - Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma. Wayne Furman, MD, hopes that the humanized anti-disialoganglioside (anti-GD2) monoclonal antibody hu14.18K322A provides a breakthrough for children wi...

Rare Cancers Report: Pediatric Neuroblastoma
https://www.onclive.com/view/rare-cancers-report-pediatric-neuroblastoma

Feb 3rd, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and p...

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment
https://www.onclive.com/view/yale-cancer-center-researchers-show-receptor-structure-reveals-new-targets-for-cancer-treatment

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...

see more →

Patient Education  3 results see all →